Agenus shared on LinkedIn:
“Looking ahead to ESMOGI25: Dr. Benjamin Schlechter from Dana-Farber Cancer Institute will present new long-term follow-up data from the Phase 1 study with microsatellite stable (MSS) metastatic colorectal cancer patients.
Stop by our poster next week at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain.
Learn more about the abstract.”
More posts featuring ESMOGI25.